-
Publication Venue For
-
Time-To-Event Data: An Overview and Analysis Considerations.
2021
-
SMARCA4 and other SWI/SNF family genomic alterations in non-small cell lung cancer: Clinicopathological characteristics and outcomes to immune checkpoint inhibition.
2021
-
Clinical Significance of Lung-RADS Category 3 Lesions in the National Lung Screening Trial.
2021
-
A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC..
16:419-427.
2021
-
Statistical Considerations for Subgroup Analyses..
16:375-380.
2021
-
Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK+ NSCLC..
16:156-161.
2021
-
Multi-Institutional Prospective Validation of Prognostic mRNA Signatures in Early Stage Squamous Lung Cancer (Alliance)..
15:1748-1757.
2020
-
Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations..
15:1611-1623.
2020
-
Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center..
15:1037-1053.
2020
-
New Approaches to SCLC Therapy: From the Laboratory to the Clinic..
15:520-540.
2020
-
Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis..
15:637-648.
2020
-
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort..
15:426-435.
2020
-
EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach..
15:29-49.
2020
-
Outcomes for Surgery in Large Cell Lung Neuroendocrine Cancer..
14:2143-2151.
2019
-
Pathologic Considerations and Standardization in Mesothelioma Clinical Trials..
14:1704-1717.
2019
-
Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting..
14:1718-1731.
2019
-
SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)..
14:1839-1846.
2019
-
A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce..
14:1343-1353.
2019
-
The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation..
14:1172-1183.
2019
-
Electromagnetic Navigation Bronchoscopy for Peripheral Pulmonary Lesions: One-Year Results of the Prospective, Multicenter NAVIGATE Study..
14:445-458.
2019
-
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032..
14:237-244.
2019
-
Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer..
14:298-303.
2019
-
Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma..
14:25-36.
2019
-
Minimally Invasive Approaches Do Not Compromise Outcomes for Pneumonectomy: A Comparison Using the National Cancer Database..
14:107-114.
2019
-
Survival Comparison in Patients with Stage IV Lung Cancer in Academic versus Community Centers in the United States..
13:1842-1850.
2018
-
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation..
13:1655-1667.
2018
-
Predictors of Physical and Functional Loss in Advanced-Stage Lung Cancer Patients Receiving Platinum Chemotherapy..
13:1294-1301.
2018
-
Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC..
13:1171-1182.
2018
-
New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center..
13:1189-1203.
2018
-
Time-to-Treatment-Failure and Related Outcomes Among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711)..
13:996-1003.
2018
-
Progress in the Management of Early-Stage Non-Small Cell Lung Cancer in 2017..
13:767-778.
2018
-
Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy..
13:660-675.
2018
-
Improved Survival of Stage I Non-Small Cell Lung Cancer: A VA Central Cancer Registry Analysis..
12:1814-1823.
2017
-
Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer..
12:1806-1813.
2017
-
Rethinking Autoantibody Signature Panels for Cancer Diagnosis..
12:1011-1014.
2017
-
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance)..
12:843-849.
2017
-
Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance)..
12:704-713.
2017
-
The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients..
12:689-696.
2017
-
Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation..
12:368-374.
2017
-
ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC: Topic: Medical Oncology..
11:S250-S251.
2016
-
PS01.61: Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now (REVOLUTION): Registry Study in Progress: Topic: Medical Oncology..
11:S308-S309.
2016
-
PS01.76: Impact of Chemotherapy Intensity on Progression and Survival in Metastatic Non-Small Cell Lung Cancer: A Systematic Review: Topic: Medical Oncology..
11:S319.
2016
-
Impact of Race on Treatment and Survival among U.S. Veterans with Early-Stage Lung Cancer..
11:1672-1681.
2016
-
Location of the Tumor is a "Central" Predictor of Nodal (N1) Upstaging..
11:e89-e90.
2016
-
60PD Inhibition of pEGFR in paired tumour biopsies from TKI treatment-naïve EGFR mutant NSCLC patients treated with gefitinib (EGFR inhibitor) or gefitinib in combination with durvalumab (anti-PD-L1)..
11:S80-S81.
2016
-
Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE)..
11:361-369.
2016
-
The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification..
11:142-154.
2016
-
Refining Prognosis in Lung Cancer: A Report on the Quality and Relevance of Clinical Prognostic Tools..
10:1576-1589.
2015
-
Reply to "Prognostic Value of Fluorodeoxyglucose-Positron Emission Tomography"..
10:e102.
2015
-
Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung Cancer..
10:1067-1075.
2015
-
Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer..
10:1099-1106.
2015
-
FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer..
10:897-902.
2015
-
Endobronchial ultrasound versus mediastinoscopy for mediastinal nodal staging of non-small-cell lung cancer..
10:331-337.
2015
-
A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG)..
10:143-147.
2015
-
Adjuvant chemotherapy is associated with improved survival after esophagectomy without induction therapy for node-positive adenocarcinoma..
10:181-188.
2015
-
Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer..
9:1443-1448.
2014
-
Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study..
9:1354-1362.
2014
-
Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study..
9:1332-1339.
2014
-
Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer..
9:1195-1201.
2014
-
Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data..
9:702-709.
2014
-
Redistribution of health care costs after the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2005..
9:512-518.
2014
-
CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer..
9:214-221.
2014
-
The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) response to the USPSTF recommendations..
9:141-143.
2014
-
A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer..
8:1510-1518.
2013
-
Prognostic validation of the body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index in inoperable non-small-cell lung cancer..
8:1545-1550.
2013
-
A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904..
8:1043-1049.
2013
-
Impact of PET staging in limited-stage small-cell lung cancer..
8:899-905.
2013
-
Polymorphisms in mTORC1 genes modulate risk of esophageal squamous cell carcinoma in eastern Chinese populations..
8:788-795.
2013
-
Treatment modalities for T1N0 esophageal cancers: a comparative analysis of local therapy versus surgical resection..
8:796-802.
2013
-
Variability in the treatment of elderly patients with stage IIIA (N2) non-small-cell lung cancer..
8:744-752.
2013
-
Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206..
8:102-108.
2013
-
Cigarette smoking associated with lung adenocarcinoma in situ in a large case-control study (SFBALCS)..
7:1352-1360.
2012
-
Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy..
7:1141-1147.
2012
-
Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414)..
7:906-912.
2012
-
CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304..
7:649-654.
2012
-
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report..
7:755-759.
2012
-
Recurrence dynamics for non-small-cell lung cancer: effect of surgery on the development of metastases..
7:723-730.
2012
-
Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer..
7:376-381.
2012
-
Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib..
6:2135-2137.
2011
-
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304..
6:1902-1906.
2011
-
Comparison of demographic characteristics, surgical resection patterns, and survival outcomes for veterans and nonveterans with non-small cell lung cancer in the Pacific Northwest..
6:1726-1732.
2011
-
The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer..
6:1687-1690.
2011
-
The use of electrocautery as the primary ablation modality for malignant and benign airway obstruction..
6:1516-1520.
2011
-
Pathologic response after neoadjuvant carboplatin and weekly paclitaxel for early-stage lung cancer: a Brown University oncology group phase II study..
6:1432-1434.
2011
-
Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer..
6:1267-1273.
2011
-
Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer..
6:781-785.
2011
-
How well does the new lung cancer staging system predict for local/regional recurrence after surgery?: A comparison of the TNM 6 and 7 systems..
6:757-761.
2011
-
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma..
6:244-285.
2011
-
Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer..
6:384-386.
2011
-
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307..
5:1655-1661.
2010
-
National Lung Cancer Screening Trial American College of Radiology Imaging Network Specimen Biorepository originating from the Contemporary Screening for the Detection of Lung Cancer Trial (NLST, ACRIN 6654): design, intent, and availability of specimens for validation of lung cancer biomarkers..
5:1502-1506.
2010
-
Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304)..
5:1644-1648.
2010
-
Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial..
5:1382-1390.
2010
-
Tumor necrosis and cavitation after stereotactic body radiation therapy..
5:1100-1102.
2010
-
Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633..
5:810-817.
2010
-
A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602)..
5:380-384.
2010
-
Preoperative radiation therapy and chemotherapy for pulmonary blastoma: a case report..
5:282-283.
2010
-
Timing of local and distant failure in resected lung cancer: implications for reported rates of local failure..
5:211-214.
2010
-
Molecular analysis-based treatment strategies for the management of non-small cell lung cancer..
4:S1029-S1039.
2009
-
Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer..
4:1117-1125.
2009
-
Giant thoracic liposarcoma treated with induction chemotherapy followed by surgical resection..
4:768-769.
2009
-
A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104..
4:220-226.
2009
-
Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial..
4:198-202.
2009
-
Formation of a bronchoesophageal fistula following concurrent radiation and chemotherapy for lung cancer in the setting of Behçet's disease..
3:1361-1362.
2008
-
Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430..
3:1301-1307.
2008
-
Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303)..
3:1159-1165.
2008
-
Intrathoracic desmoid tumor: brief report and review of literature..
3:656-659.
2008
-
Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904..
3:417-421.
2008
-
Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901..
3:158-162.
2008
-
Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project..
3:6-12.
2008
-
Frequency and prognostic significance of preoperatively detected enlarged regional lymph nodes in patients with pathological stage I non-small cell lung cancer following resection..
2:1103-1106.
2007
-
The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer..
2:686-693.
2007
-
Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002..
2:645-651.
2007
-
Preoperative exercise Vo2 measurement for lung resection candidates: results of Cancer and Leukemia Group B Protocol 9238..
2:619-625.
2007
-
A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer..
2:520-525.
2007
-
Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence..
2:499-505.
2007
-
A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy..
2:210-220.
2007
-
Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria..
1:S13-S19.
2006
-
Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment..
1:S20-S26.
2006
-
Impact of a multidisciplinary thoracic oncology clinic on the timeliness of care..
1:692-696.
2006
-
Targeting anemia in patients with lung cancer..
1:716-725.
2006
-
Integration of biomarkers and imaging..
1:78-80.
2006
-
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC.
2021